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Copyright © 200? JCBN Summary A triple therapy based on a proton pump inhibitor (PPI), amoxicillin (AMPC),
and clarithromycin (CAM) is recommended as a first-line therapy for Helicobacter pylori
(H. pylori) eradication and is widely used in Japan. However, a decline in eradication rate
associated with an increase in prevalence of CAM resistance is viewed as a problem. We
investigated CAM resistance and eradication rates over time retrospectively in 750 patients
who had undergone the triple therapy as first-line eradication therapy at Nagoya City
University Hospital from 1995 to 2008, divided into four terms (Term 1: 1997–2000, Term 2:
2001–2003, Term 3: 2004–2006, Term 4: 2007–2008). Primary resistance to CAM rose
significantly over time from 8.7% to 23.5%, 26.7% and 34.5% while the eradication rate
decreased significantly from 90.6% to 80.2%, 76.0% and 74.8%. Based on the PPI type,
significant declines in eradication rates were observed with omeprazole or lansoprazole,
but not with rabeprazole. A decrease in the H. pylori eradication rate after triple therapy
using a PPI + AMPC + CAM has been acknowledged, and an increase in CAM resistance is
considered to be a factor. From now on, a first-line eradication regimen that results in a higher
eradication rate ought to be investigated.
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Introduction
The greatest association of Helicobacter pylori (H. pylori)
infection is with peptic ulcer disease. Recently, the associa-
tion between H. pylori and the development of gastric cancer
is more clearly established than before, and by the announce-
ment of the Japanese Society for Helicobacter Research,
H. pylori eradication should be undertaken in all subjects
who are infected [1, 2]. The treatment to eradicate H. pylori
by a triple therapy using a proton pump inhibitor (PPI),
amoxicillin (AMPC) and clarithromycin (CAM) was
approved and covered by insurance in Japan in November,
2000. In February 2003, the eradication therapy went into
broad use as a result of the eradication guidelines of the
Japanese Society for Helicobacter Research. The initial
eradication rate was good at about 90% [3], but a decline
in eradication rate attributable to an increase in CAM
resistance was pointed out. Consequently, the Japanese
Society for Helicobacter Research conducted sensitivityM. Sasaki et al.
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surveillance from 2002 through 2006 in order to determine
the prevalence of H. pylori drug resistance in Japan. The
results revealed that the CAM resistance rate from 2002 to
2003 was 18.9%, followed by 21.1% in 2003–2004, 27.7%
in 2004–2005 [4]. The reports also demonstrated that the
CAM resistance rate in Japan since 2003 exceeded 20%, the
condition the Maastricht III Consensus Report recommends
the triple therapy using PPI, AMPC and CAM [5]. In such a
situation (CAM resistance rate >20%), it is recommended
that drug sensitivity tests be carried out prior to eradication
[5], but in Japan sensitivity testing is not common because
eradication therapies other than the PPI, AMPC, and CAM
triple therapy are not approved for the first-line eradication
therapy. In this study, we conducted a retrospective analysis
of the status of eradication rate by PPI, AMPC, and CAM in
our hospital in Japan, where the rate of CAM resistance is
high.
Materials and Methods
We retrospectively investigated the H. pylori eradication
rate over time in 750 patients, who had been diagnosed as
H. pylori-infected by at least one positive result from culture
test, microscopy or 13C-urea breath test (UBT). The 750
patients had received the triple therapy based on a PPI
(omeprazole (OPZ) 20 mg or lansoprazole (LPZ) 30 mg or
rabeprazole (RPZ) 10 mg twice as day), AMPC (750 mg
twice as day), and CAM (200 mg or 400 mg twice a day) at
Nagoya City University Hospital from January, 1997 until
December, 2008. Successful eradication was determined by
performing a UBT following the first month after eradica-
tion, and Δ<2.5‰ was defined as successful eradication. We
also investigated the relationship between the eradication
rate and the H. pylori CAM primary resistance (from the flat
dilution method, MIC >8 μg/ml) in four terms detected at
Nagoya City University Hospital from January 1997 until
December 2008. Terms were divided as follows; Term 1:
1997–2000, before eradication therapy was approved and
covered by insurance in Japan; Term 2: 2001–2003, the first
half of period when only omeprazole and lansoprazole were
approved, Term 3: 2004–2006, the latter half of period when
only omeprazole and lansoprazole were approved; Term 4:
2007–2008, after rabeprazole was approved. The eradication
rate by type of PPI was evaluated as well.
The Kruskal-Wallis test and the χ2 test were used for
the statistical analysis. p<0.05 was considered statistically
significant.
Results
Table 1 presents the patients’ background in this study.
491 men and 259 women with the average age of 56.1 ± 14.2
years were enrolled in the study. The classification of
disorders were gastric ulcers (258/750, 34.4%), duodenal
ulcers (188/750 25.1%), gastroduodenal ulcers (57/750,
7.6%), other gastrointestinal disorders (247/750, 32.9%).
The patients with gastrointestinal disorders mainly comprised
patients with atrophic gastritis or patients having undergone
endoscopic treatment for a gastric tumor. 41 patients did not
visit for the evaluation of H. pylori eradication. 709 patients
were tested by UBT to determine whether the H. pylori was
eradicated, and successful eradication was assessed in 559
of these patients. We divided the study into the four terms of
1997 to 2000 (Term 1), before H. pylori eradication therapy
was indicated and covered by insurance in Japan; the first
half of the period from 2001 to 2006, when eradication
therapy was based on OPZ and LPZ (Term 2, from 2001 to
2003); and the second half of that (2004–2006, Term 3); and
2007 and later years (Term 4), when treatment with RPZ was
approved for insurance coverage. There were no differences
Table 1. Patients’ background
*p<0.05 significantly different compared with –2000 group.
Total –2000 –2003 –2006 2007–
Number of Patients 750 103 197 267 183
Age 56.6 ± 14.2 53.0 ± 13.4 55.2 ± 14.2 58.1 ± 13.4* 57.8 ± 15.4*
Sex (M/F) 491/259 63/40 134/63 182/85 112/71
Disorder
Gastric ulcer 258 
(34.4%)
21 
(20.4%)
78 
(39.6%)
81 
(30.3%)
78 
(42.6%)
Duodenal ulcer 188 
(25.1%)
28 
(27.2%)
53 
(26.9%)
58 
(21.7%)
49 
(26.8%)
Gastroduodenal ulcer 57 
(7.6%)
11 
(10.7%)
14 
(7.1%)
21 
(7.9%)
11 
(6.0%)
Other 247 
(32.9%)
43 
(41.7%)
52 
(26.4%)
107 
(40.1%)
45 
(24.6%)12-Year H. pylori Eradication Rate
Vol. 47, No. 1, 2010
55
based on gender or type of disorder from Term 1 to Term 4,
but the ages were significantly higher in Terms 3 and 4
compared it in Term 1. Eradication rates significantly
declined over time from 90.6% to 80.2%, 76.0% and 74.8%
between Term 1 and Term 4 (Fig. 1). On the other hand,
primary CAM resistance rose significantly over time
between 1997 and 2008 from 8.7% in Term 1, prior to 2000;
23.5% in Term 2; 26.7% in Term 3; and 34.5% in Term 4
(Fig. 2). In 159 patients who were tested for CAM suscepti-
bility, the eradication rate in those with CAM susceptibility
was 86.7% while the eradication rate in those with CAM-
resistant bacteria was 25.0%, which resulted in a significant
difference. Therefore, the rise in primary CAM resistance is
considered to be a major factor leading the decline in the
first-line eradication rate based on triple therapy with the
PPI, AMPC, and CAM. We also investigated the differences
Fig. 1. Eradication rates significantly declined from 90.6% (1997–2000) to 80.2% (2001–2003), 76.0% (2004–2006) and 74.8%
(2007–2008). The eradication rate of CAM-resistant bacteria (25.0%) was significant lower than that of CAM susceptibility
(86.7%). CAM-S, clarithromycin susceptibility; CAM-R, clarithromycin resistance.
Fig. 2. Primary CAM resistance rose significantly from 8.7%
(1997–2000) to 23.5% (2001–2003), 26.7% (2004–
2006), and 34.4% (2007–2008). Fig. 3. Eradication rates by OPZ/LPZ significantly decline from
91.2% (1995–2000) to 80.2% (2001–2003), 76.0%
(2004–2006) and 69.0% (2007–2008). On the other
hand, no significant difference was found in the RPZ
eradication rates between the term of before 2000 and
after 2007. O/LAC, omeprazole or lansoprazole +
amoxicillin + clarithromycin regimen. RAC, rabeprazole +
amoxicillin + clarithromycin regimen.M. Sasaki et al.
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over time in the eradication rate for the different types of
PPIs. RPZ was not used for eradication treatment from 2000,
when eradication therapy was approved in Japan, until 2007,
when RPZ was approved for insurance coverage. Therefore,
we compared the eradication rates by RPZ for Term 1 with
Term 4. For OPZ and LPZ, eradication rates were compared
in all four terms. A significant decline over time in eradica-
tion rates by OPZ/LPZ from Terms 1 to Term 4 was
observed; 91.2%, 80.2%, 76.0% and 69.0%. On the other
hand, no significant difference was found in the RPZ eradi-
cation rates; 89.2% in Term 1 and 79.4% in Term 4 (Fig. 3).
Discussion
The H. pylori eradication rate by triple therapy based on
a PPI, AMPC and CAM is thought to be affected by age,
smoking habits, drug compliance, polymorphisms of the
CYP2C19 gene, and drug susceptibility, and CAM resis-
tance, in particular, is viewed to have a large effect on the
eradication rate [6–10]. That arises from the big deteriora-
tion in eradication rate from about 80.6%–98.3% for CAM-
susceptible bacteria to 0%–33.3% for CAM-resistant
bacteria [11,  12]. In the 2005 Maastricht III Consensus
Report, triple therapy based on a PPI, AMPC, and CAM
were recommended as the primary eradication drugs in areas
where CAM resistance is <20% [5]. In a report on the
eradication rate in the United Kingdom over the 11 years
from 1991 to 2001, a good eradication rate of 89.9% was
reported for triple therapy using a PPI, AMPC, and CAM
when the CAM resistance ranged 3.8–10.3% [13]. In the
present study period, the CAM resistance had been low at
8.7% with a good eradication rate at 90.6% for the triple
therapy before 2000, when eradication therapy was
approved in Japan. However, after that, the CAM resistance
rate rose over 20%, the surveillance by the Japanese Society
for Helicobacter Research revealed [6]. In our facility, as
well, CAM resistance had exceeded 20% in 2000 and
reached >30% over the past two years, which resulted in
the remarkable decline in eradication rate along, falling to
the 70% level. Triple therapy with a PPI, AMPC and CAM
needs to be re-examined in Japan. Triple therapy using a
PPI, AMPC, and metronidazole (MNZ) is used in second-
line eradication, and a high eradication rate over 90% has
been reported in Japan [14–16]. In addition, new approaches
to improve the eradication rate by concomitant with a
mucoprotective drug or lactobacillus are attempted [17, 18].
Triple therapy using MNZ as first line eradication and new
regimen using quinolone like levofloxacin, gatifloxacin,
sitafloxacin or garenoxacin need to be developed [19, 20].
Mean age of patients taking significantly rose in Term 3
and 4 compared to Term 1 in the present study as seen in
table 1. However, Broutet et al. [21] reported higher failure
rate among young patients, therefore, the significant higher
age in Term 3 and 4 was considered not to have influenced
the lowering eradication rate in the present study.
On the other hand, the eradication rate for triple therapies
is reported to depend on the degree of acid secretion
suppression, in addition to CAM resistance [22], and the
importance of acid secretion suppression has also drawn
attention. The effect of suppressing acid secretion by a PPI
was reported to rely on a polymorphism of the CYP2C19
gene [23]. That the eradication rates for triple therapy based
on a PPI, AMPC and CAM differ due to polymorphisms of
the CYP2C19 gene is also reported in a meta-analysis [24].
In patients with CAM-resistant bacteria, in particular, the
eradication rate is reported to be greatly affected by poly-
morphisms of the CYP2C19 gene [25]. It was shown that the
eradication rate for a double eradication therapy of PPI and
AMPC is affected by the extent to which acid secretion can
be suppressed [26], and that is thought to be because the
PPI's ability to suppress acid secretion affects the eradication
rate more for CAM-resistant bacteria. In Japan, OPZ, LPZ
and RPZ are used in the eradication treatment, but RPZ is
reported to be less likely affected by CYP2C19 than the
other two PPIs [27, 28]. In fact, a meta-analysis reported the
less influence of CYP2C19 polymorphism on triple therapy
using RPZ unlike the case of OPZ or LPZ [24]. In Japan,
there is a great deal of variety in polymorphisms of the
CYP2C19 gene [29], and that is why we investigated
eradication rates in triple therapy groups and in the group
using RPZ and the other groups using the OPZ or LPZ.
While the eradication rates in OPZ and LPZ groups
decreased significantly over time, no apparent decline in
eradication rate was seen for the RPZ group. Less influence
of CYP2C19 polymorphisms on RPZ might explain the
reason. Also, RPZ itself is indicated to possess antibiotic
effects of against H. pylori, and it might have helped as
well [30]. However, we did not conduct detailed investiga-
tions because it was a retrospective study, nor did we
measure CYP2C19 polymorphisms, and H. pylori drug
susceptibility tests were carried out only for some cases.
In the current situation where prevalence of primary
resistance to CAM increased, it was difficult to ascertain
the reasons why differences arose in the effectiveness of
H. pylori eradication by acid secretion-suppressing agents
and triple therapy based on a PPI, AMPC, and CAM.
However, the eradication rate for large-scale triple therapy
using RPZ is reported to be good and to be ≥90%, in spite of
increase in the CAM resistance rate in recent years [31]. In
addition, a prospective study reported a higher eradication
rate of 91% with RPZ than it of 81% with LPZ prior to our
report [12]. The selection of a PPI should also be important
in first line eradication today, and we need to make it clearer
hereafter.
The present study demonstrated the evident decline in
eradication rates for the triple therapy using a PPI, AMPC12-Year H. pylori Eradication Rate
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and CAM in Japan, and the increase in CAM resistance rate
is considered to be associated with the lower eradication
rate. The first line eradication with new regimens must be
developed and used. At the same time, PPI from which a
higher eradication rate can be obtained should be selected
from current regimen as well.
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